» Articles » PMID: 23707776

Ascending Monoaminergic Systems Alterations in Alzheimer's Disease. Translating Basic Science into Clinical Care

Overview
Date 2013 May 28
PMID 23707776
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Extensive neuropathological studies have established a compelling link between abnormalities in structure and function of subcortical monoaminergic (MA-ergic) systems and the pathophysiology of Alzheimer's disease (AD). The main cell populations of these systems including the locus coeruleus, the raphe nuclei, and the tuberomamillary nucleus undergo significant degeneration in AD, thereby depriving the hippocampal and cortical neurons from their critical modulatory influence. These studies have been complemented by genome wide association studies linking polymorphisms in key genes involved in the MA-ergic systems and particular behavioral abnormalities in AD. Importantly, several recent studies have shown that improvement of the MA-ergic systems can both restore cognitive function and reduce AD-related pathology in animal models of neurodegeneration. This review aims to explore the link between abnormalities in the MA-ergic systems and AD symptomatology as well as the therapeutic strategies targeting these systems. Furthermore, we will examine possible mechanisms behind basic vulnerability of MA-ergic neurons in AD.

Citing Articles

Dopaminergic deficits along the spectrum of Alzheimer's disease.

Pilotto A, Galli A, Sala A, Caminiti S, Presotto L, Liguori C Mol Psychiatry. 2025; .

PMID: 39890920 DOI: 10.1038/s41380-025-02913-5.


Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.

Jacob C, Tollenaere M, Kachar H, Potier M, De Deyn P, Van Dam D Heliyon. 2025; 11(1):e41445.

PMID: 39850411 PMC: 11755057. DOI: 10.1016/j.heliyon.2024.e41445.


Differential involvement of central and peripheral catecholamines between Alzheimer's disease and vascular dementia.

Hong X, Li S, Li T, Chen W, Li Y, Wang Z Heliyon. 2024; 10(19):e38843.

PMID: 39398044 PMC: 11471233. DOI: 10.1016/j.heliyon.2024.e38843.


Examining resilience to Alzheimer's disease through the lens of monoaminergic neuromodulator systems.

Crawford J, Berry A Trends Neurosci. 2024; 47(11):892-903.

PMID: 39368845 PMC: 11563896. DOI: 10.1016/j.tins.2024.09.004.


Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms.

Saggu S, Bai A, Aida M, Rehman H, Pless A, Ware D Geroscience. 2024; 47(1):457-482.

PMID: 39331291 PMC: 11872848. DOI: 10.1007/s11357-024-01359-x.